Huntington's disease (HD) is a dominantly inherited neurodegenerative disease caused by an expanded CAG repeat in HTT. Many clinical characteristics of HD such as age at motor onset are determined largely by the size of HTT CAG repeat. However, emerging evidence strongly supports a role for other genetic factors in modifying the disease pathogenesis driven by mutant huntingtin. A recent genome-wide association analysis to discover genetic modifiers of HD onset age provided initial evidence for modifier loci on chromosomes 8 and 15 and suggestive evidence for a locus on chromosome 3. Here, genotyping of candidate single nucleotide polymorphisms in a cohort of 3,314 additional HD subjects yields independent confirmation of the former two loci and moves the third to genome-wide significance at MLH1, a locus whose mouse orthologue modifies CAG length-dependent phenotypes in a Htt-knock-in mouse model of HD. Both quantitative and dichotomous association analyses implicate a functional variant on $32% of chromosomes with the beneficial modifier effect that delays HD motor onset by 0.7 years/allele. Genomic DNA capture and sequencing of a modifier haplotype localize the functional variation to a 78 kb region spanning the 3'end of MLH1 and the 5'end of the neighboring LRRFIP2, and marked by an isoleucinevaline missense variant in MLH1. Analysis of expression Quantitative Trait Loci (eQTLs) provides modest support for altered regulation of MLH1 and LRRFIP2, raising the possibility that the modifier affects regulation of both genes. Finally, polygenic modification score and heritability analyses suggest the existence of additional genetic modifiers, supporting expanded, comprehensive genetic analysis of larger HD datasets. †
Introduction
Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder in which an unstable expanded CAG trinucleotide repeat of > 35 units in HTT, the 4p16.3 gene encoding huntingtin (1) , precipitates a characteristic movement disorder and premature death (2, 3) . The length of the CAG expansion is the primary determinant of the rate of the HD disease process since its size is inversely correlated with the age at onset of neurologic symptoms (4) (5) (6) (7) (8) . However, other genetic factors also play a role in influencing the time to onset (9, 10) . A recent genomewide association (GWA) analysis of the difference between actual and CAG-predicted age at onset in $4,000 HD individuals identified genome-wide significant modifier loci, one with two independent modifier signals on chromosome 15 and a single modifier signal on chromosome 8 (11) . In addition, a suggestive association signal was detected in chromosome 3p22.2 near mutL homolog 1 (MLH1) (11) , known for its involvement in DNA mismatch repair (12) . Dominant loss of function mutation of MLH1 is associated with Lynch Syndrome (hereditary nonpolyposis colon cancer type 2 or HNPCC2; MIM#609310), in which tumors display instability of dinucleotide repeats. The 3p22 GWA signal in our study contributed to pathway analyses that further highlighted a role for DNA maintenance processes in HD modification, supporting the hypothesis that somatic CAG instability may influence onset age suggested previously by a correlation between high instability of the expanded repeat in HD postmortem brain tissue and an earlier age at motor onset (13) . Moreover, genetic ablation of the murine MLH1 homolog, Mlh1, in Htt CAG repeat knock-in mice eliminated instability of the expanded repeat and ameliorated nuclear huntingtin staining, a striatal disease phenotype (14) . To obtain independent confirmation of the loci on chromosomes 8 and 15 and to test the significance of several other potential modifier loci, especially that in 3p22.2, we employed the Fluidigm platform to genotype individual candidate single nucleotide polymorphisms (SNPs) in a large independent cohort of HD individuals: 3,314 participants from the European Huntington's Disease Network (EHDN) Registry collection.
Results
Single SNP association analysis reveals a 3rd genomewide significant modifier locus Study subjects analysed here displayed distributions of age at onset corrected for CAG repeat size (i.e. residual age at onset) and minor allele frequencies (MAF) comparable to the previous GWA samples (Supplementary Material, Figs S1-S2). A number of the top scoring SNPs from the original GWA study (11, 15) were not suitable for the Fluidigm genotyping platform (https:// www.fluidigm.com/; date last accessed July 24, 2017), so we substituted other variants that captured the same modifier signals. Ultimately, we genotyped the replication set for rs34852161 at the chromosome 8 locus, rs150393409 and rs35811129 representing independent modifier effects in the same region of chromosome 15, rs116483964 and rs1799977 at the 3p22.2 locus and individual SNPs at 57 additional loci chosen for being amenable to the platform and having a P-value < 0.005 in either quantitative or dichotomous analysis from the original GWA (11) (Supplementary Material, Table S1 ). Quantitative association analysis using residual age at motor onset as the phenotype revealed nominally significant scores for rs34852161 on chromosome 8 and rs150393409 on chromosome 15, while rs35811129 on chromosome 15 yielded genome-wide significance (P-value 2E-10) in the replication set (Table 1 ; Supplementary Material, Table S2 ). In meta-analysis with the prior GWA study, all three yielded genome-wide significant scores, confirming the modifier effects reported previously (11) . At the 3p22.2 locus, both rs1799977 in MLH1 and rs116483964 in the adjacent LRRFIP2 exhibited nominally significant P-values (Table 1) . Meta-analysis combining the replication data and GWA analysis results raised both to genomewide significance (8.84E-09 and 1.19E-08, respectively) ( Table 1 ; Fig. 1A , filled red circles).
As this finding adds an additional locus to the list of genome-wide significant HD modifiers, we also carried out dichotomous analysis to evaluate the possibility that the significant association in quantitative analysis was driven by a few individuals with extreme residuals. Comparison of allele frequencies between the top and bottom 20% phenotypic extreme samples from the combined data (1,478 samples for each extreme group) also revealed genome-wide significance for rs1799977 (P-value, 5.3E-09) and rs116483964 (P-value, 5.6E-09) (Table 2A ). Conditional analysis demonstrated that both SNPs appear to capture a single modifier effect (Table 2B ). The minor allele of each SNP was associated with delaying age at onset by approximately 0.7 years, explaining 0.5% of the residual age at onset in the combined data set. Of the remaining 57 independent loci tested, none attained genome-wide significance in the meta-analysis of GWA and Fluidigm data sets, although three were nominally significant (P-value < 0.05) in the latter (Supplementary Material, Table S2 ).
Narrowed localization of the Chr3 functional variation responsible for modification of HD
The rs1799977 minor allele is a missense (isoleucine to valine) variant in MLH1, with a reported allele frequency of about 32.5% in 1,000 Genomes Project Europeans. As noted above, MLH1 is involved in DNA mismatch repair (12, 16) and HD CAG repeat instability (14) , and inactivating mutations are present in some Lynch Syndrome families (17) . SNP rs116483964, with a comparable minor allele frequency (MAF), is in an early intron of the immediately adjacent gene, LRRFIP2, whose product, Leucine Rich Repeat (In FLII) Interacting Protein 2, is involved in proteinprotein interactions that regulate Wnt-signaling (18) . LRRFIP2 is deleted together with MLH1 as a founder mutation in some Portuguese Lynch syndrome families (19) . In the original GWA study, there were other SNPs with comparable P-values at this locus that were not amenable to genotyping on the Fluidigm platform. To seek the variation responsible for the modifier effect, we selected 7 unrelated HD subjects homozygous for the Table S3 ). Encompassed by this haplotype were the minor alleles for the seven top scoring markers from the GWA, all of which have a frequency of 0.31-0.32 in our HD dataset ( Table 3) . Each of these markers shows a striking shift of the minor allele toward the 4 th quartile of the age of onset residual distribution, indicative of a contribution of a chromosome bearing this 7-marker haplotype to later than expected onset ( Table 3) . The GWA and capture sequencing data both argue that 0.31-0.32 is the frequency of the responsible functional modifier variation at this locus in European HD subjects. First, the 100 kb shared haplotype also contains many polymorphic sites of higher MAF (107 sites MAF > 0.32) in Europeans, but these all yielded weaker significance scores in both quantitative and dichotomous association analysis (Fig. 1B, filled grey circles) , indicating that signal from the allele on the modifier haplotype is diluted by the presence of the same allele on many nonmodifier chromosomes. Second, all markers with MAF < 0.31 (70 sites with MAF > 0.02) yielded weaker significance scores in the GWA analysis (Fig. 1B , open grey circles), indicating that they did not fully capture the modifier effect and arguing against the effect being contributed by only a subset of the chromosomes marked by the top SNPs. Finally, our capture sequencing of these 14 candidate modifier chromosomes did not identify any shared novel variants that could be responsible for modification (Supplementary Material, Table S3 ). Consequently, the modifier effect is likely to be due to one or more of the markers listed in Table 3 , acting either individually or together through part or all of the haplotype that they define. Although we cannot completely exclude an undetected structural variation or a change Representative transcripts with different exons in this region were obtained from RefSeq and UCSC Genome Browser.
in a simple sequence repeat, as these may remain cryptic to the capture sequencing used, we did exclude the presence of structural variations greater than a few kb using whole genome sequencing of large-insert jumping libraries (20, 21) . The most attractive candidate variant is rs1799977 since it alters the primary sequence of the MLH1 protein, may impact mildly on its interaction with PMS2 (22) and has been associated with allelic expression of the MLH1 transcript (23) . The ancestral A allele of rs1799977 specifies an isoleucine residue at position 219 that is conserved across mammals. The alternate G allele specifies valine, which is present in this conserved region of the MLH1 proteins of some reptiles, birds, fish and lower organisms, consistent with a functional but subtly different MLH1 protein.
In candidate studies, this I219V polymorphism has been tested as a low penetrance risk factor or modifier of various cancers, with mixed results, again suggestive of only a subtle functional impact (24) (25) (26) (27) (28) (29) (30) (31) (32) . Neither rs1799977 nor the other SNPs in the modifier haplotype are listed in the GWAS catalog (2017-02-13 release) as associated with genome-wide significance to cancer or other human phenotypes.
Potential effect of the modifier haplotype on gene expression
The two Chr3 markers used here both yielded significant expression Quantitative Trait Locus (eQTL) signals with expression of multiple genes in the region (MLH1, LRRFIP2, and GOLGA4) in various tissues (GTEx portal, V6; http://www.gtexpor tal.org/home/; date last accessed July 24, 2017). To examine whether the modifier haplotype contributes to any cis-eQTLs, we related the association signals for all GWA SNPs in the Chr3:36,800,000-37,800,000 region ( Fig. 1) S6 ; rs1799977). It remains uncertain which particular cell type is responsible for the modifier effect and whether there is a coincident impact on expression of any MLH1 transcript isoform. Notably, one rare transcript isoform of MLH1 is reported to overlap with LRRFIP2, suggesting the possibility that regulatory changes could in some instances affect expression of both genes. More detailed molecular studies in human HD tissues will be required to determine the precise impact(s) of this modifier haplotype on both MLH1 and LRRFIP2.
Genetic component of residual age at onset
The four independent genome-wide significant modifier signals at 3 loci explain only a small portion of the variance in residual HD age at onset. Therefore, we evaluated the explanatory power of a polygenic modification score to determine the degree to which residual age at onset is better accounted for by a composite genetic score that includes many nominally associated SNPs. Overall, the effect sizes of 61 independent SNPs (only rs1799977 was used to represent 3p22.2) in the GWA data and in the replication samples were not significantly different (sign test P-value, 0.609). Based upon effect sizes of SNPs estimated from the GWA analysis as a training set, a polygenic modification score was calculated for each of the 3,314 individuals in the Fluidigm data set. Then, residual age at onset was modeled as a function of polygenic modification score from the Fluidigm data. All 61 independent SNPs (one SNP for chromosome 3 and 60 other independent SNPs) were significant in the original GWA data (nominal P-value < 0.05) (Supplementary Material, Table S2 ), and the subsequently derived polygenic modification score explained a nominally significant amount of the variance in residual age at onset of the Fluidigm samples (P-value, 0.0157). Although somewhat biased, the polygenic modification score based on the Fluidigm samples (using SNPs with nominal P-value < 0.05) was highly significant in accounting for residual age at onset in HD subjects in the GWA data (P-value, 4.0E-26). When those missing genotypes in the Fluidigm test data set were assigned an expected genotype based upon allele frequency, the modification score became slightly more significant (Supplementary Material, Table S4 ), suggesting that missing genotypes and the smaller size of test sample might have contributed to sub-optimal performance of the polygenic modification score in the Fluidigm data test set. Therefore, in order to judge the explanatory power of the polygenic modification score, we combined the GWA and Fluidigm data, and evenly split the data at random 1,000 times to generate training sets and corresponding test sets. Polygenic modification scores were then based on SNPs that passed pre-specified P-value thresholds in the training data: 0.05, 0.01, 0.001, 0.0001, and 0.00001. As summarized in Figure 2 , the polygenic modification score became more significant and predictive as more SNPs were used to calculate individual polygenic modification score in the test samples. The top SNP alone explained approximately 1.3% of variance in residual age at onset (Fig. 2) . However, the polygenic modification score, representing the genetic predisposition to deviate from the expected age at onset for a given CAG repeat size, was yet more predictive. 
Discussion
In summary, with candidate genotyping of HD individuals we have confirmed HD modifier loci on chromosomes 8 and 15 and identified the MLH1 region of chromosome 3 as an additional genome-wide significant modifier locus, while polygenic modification score analyses suggest that increasing the sample size of the GWA could identify yet more loci. The chromosome 3 modifier locus highlights MLH1, involved in brain tissue CAG instability in Htt knock-in mice (14), consistent with the hypothesis that a functional impact of genetic variation in the modifier haplotype, via effects on CAG instability in the brains of HD patients, may alter CAG repeat size and thereby affect the rate of the disease process (13) . This hypothesis is supported by the results of our GWA pathway analysis, which highlighted biological processes related to DNA maintenance (11) . The functional variation within the modifier haplotype is associated with a delay in age at onset of 0.7 years, possibly consistent with an MLH1 hypomorphic variant that reduces somatic expansion of the CAG repeat due to reduced MLH1 activity. In any event, the impact of the functional variation on MLH1 is likely to be subtle, as complete loss of function of the allele would be expected to predispose to Lynch Syndrome. The correspondence between GWA significance and eQTL results for SNPs across the region also raises the possibility that a potential regulatory effect on LRRFIP2 also contributes, either directly or indirectly via a coincident effect on MLH1, to the observed delay in onset. Clearly, additional genetic and molecular analyses will be required to test the effects of the modifier haplotype and the mechanism by which it delays the rate of HD pathogenesis. Finally, our finding that a substantial amount of variation in HD age at onset can be accounted for by genetic modification suggests that expanded GWA analysis with more subjects and therefore greater power could reveal additional modifier loci and biological networks of genes that offer bonafide therapeutic targets, validated in humans, that influence the HD disease process.
Materials and Methods

Genotyping and quality control (QC) analysis
Selection of SNPs based on the recently completed GWA analysis (11) involved choosing the most significant SNPs amenable to genotyping on the Fluidigm platform for each of the top 61 independent modifier signals. Genotyping of 67 SNPs, representing 61 independent signals, was performed by the Genomics Platform at the Broad Institute on an independent HD cohort of 3,314 HD subjects from the European Huntington's Disease Network Registry Study. All SNPs had genotyping call rate greater than 90% and Hardy-Weinberg equilibrium P-value greater than 0.01. Non-independent SNPs with lower call rates were excluded from the polygenic modification score analysis. The study was approved by the Institutional Review Board of Partners HealthCare and all subjects provided informed consent for participation in HD research.
Residual age at motor diagnosis as a phenotype for association analysis
Age at onset of motor signs was based on rater estimation where available (1,443 subjects). In the absence of a rater estimate, we used age at onset data provided by family members (63 subjects) or patients (1,808 subjects). Predicted onset age was based on a phenotypic regression model describing the relationship between CAG repeat on the expanded chromosome and recorded age at onset (6) . Predicted age at onset was subtracted from observed age at onset to calculate the residual age at onset of motor signs, whose deviation from expectation represents the individual HD patient's level of modification of age at onset. For stringent replication analysis, we analysed HD subjects with 40-55 CAG repeats with residual age at onset values within the range of the initial GWA data; since the most extreme data points have a greater potential for representing data entry or transcription errors, we excluded 5 subjects with extreme onset residuals beyond the range seen in the original GWA (Supplementary Material, Fig. S1 ).
Association analysis, meta-analysis, conditional analysis, and extreme dichotomous analysis
In the Fluidigm data set, residual age at onset was modeled as function of a test SNP (additive model) and sex using a linear regression model. Main effect for sex was not significant in any association models. The small number of SNPs chosen for Fluidigm typing for the replication study were not sufficiently informative to distinguish sub-populations (data not shown). However, we reasoned that the discovery data set and replication data set have similar characteristics in terms of ancestry because of most individuals were from European countries. In addition, comparison of allele frequencies of replication SNPs in discovery and replication data sets revealed highly strong positive correlation (Supplementary Material, Fig. S2 ), suggesting overall ancestry similarities between the two data sets. Subsequently, meta-analysis was performed by combining previous GWA results (11) and the current association results using the METAL program (http://genome.sph.umich.edu/wiki/ METAL_Documentation; date last accessed July 24, 2017) (33). Genome-wide significance was judged by meta-analysis P-value of 5E-8. To evaluate independence of chromosome 3 SNPs, GWA data and Fluidigm data were combined to perform conditional analyses. Briefly, residual age at onset was modeled as a function of either 1) rs1799977, 2) rs116483964, and 3) rs1799977 and rs116483964 together. Fixed effect linear regression models with sex covariate were constructed for conditional analysis. In addition, for chromosome 3 SNPs, we combined GWA data and Fluidigm data to perform combined extreme dichotomous analysis in which data were sorted based on the residual age at onset phenotype, and samples with the top and bottom 20% (7,272 regions) were fed into the program for least stringent probe design, generating 14,544 probes (covering 89.79% of the target region). Lastly, remaining regions were used for probe design without any stringency (3,276 probes covering 100% of target region). Thus, repeat sequences are likely to be captured by probes designed based on no stringency. In order to focus on unique sequence but still capture the entire region, we replicated probe sets designed by most, moderate, and least stringent parameters. Target DNA capture/enrichment was based on the SureSelect method (SureSelect XT2 Target Enrichment System) (35) . Briefly, each genomic DNA sample was sheared to produce smaller fragments, and indexed for multiplexing. Subsequently, pooled indexed DNA was hybridized with capture probes, and DNA-probe complexes were pulled down using magnetic streptavidin beads. Enriched multiplexed libraries were sequenced for 100 bp paired-end sequencing using Illumina HiSeq at the Broad Institute. Mean per base coverage was 174.7; 94.0% and 97.4% of the region has at least 10X and 5X coverages, respectively. Sequencing data were then analysed using the Genome Analysis Toolkit (https://software.broadinstitute.org/gatk/; date last accessed July 24, 2017). We followed the Best Practices workflow to perform QC analysis, variant discovery, and genotype calling (36) .
Comparison of HD GWA modification signals to tissue eQTL signals
To determine whether modification of HD captured by significant chromosome 3 SNPs might be mediated by differential expression levels of genes in the region, we compared GWA association signals to HaploReg, GTEx eQTL data, and BRAINEAC exon level eQTL data. Initially, we counted the number of tissues in which a test SNP and a test gene were significantly associated using HaploReg web resources, which annotated GTEx and other eQTL data sets. Due to potential tissuespecific regulation of gene expression, directions of eQTLs were not considered. Subsequently, we evaluated the patterns of correlation between modifier GWA significances and the number of significant tissues for each corresponding SNP. Next, we analysed GTEx data focusing on brain regions and two candidate genes, MLH1 and LRRFIP2. Cortex, caudate, putamen and cerebellum in GTEx data were analysed to evaluate correspondence between tissue-specific cis eQTL signals and HD modification signals. Focusing on MLH1 and LRRFIP2 in putamen, exon array expression data from BRAINEAC were analysed to test eQTL association with SNPs in the region, and subsequently eQTL signals were compared to HD GWA modifier association signals. Mapping of SNPs in eQTL data and HD GWA data was based on genomic coordinates (hg19 assembly).
Polygenic modification score analysis
In order to determine the explanatory power of a polygenic modification score in explaining the individual deviation from the expected age at onset for a given CAG size, we 1) obtained effect sizes and significances of SNPs from the initial GWA analysis (11), 2) calculated a modification score for the individual test sample (Fluidigm data) by summing the products of test SNP allele counts and corresponding effect sizes (http://zzz. bwh.harvard.edu/plink/profile.shtml; date last accessed July 24, 2017), and 3) performed linear regression analysis by modeling residual age at onset of the test samples as a function of the polygenic modification score. The same procedure was applied for polygenic modification score analysis using Fluidigm data as a training set and GWA data as a test set. Only independent SNPs were used in this analysis. When SNPs were not independent (based on conditional analysis in the initial GWA data), the SNP with the highest genotyping call rate in the Fluidigm data was chosen to represent the association signal in the region; 61 independent SNPs were used to drive polygenic modification scores of test samples. Chromosome 3p22.2 was represented by rs1799977. Among the 61 independent SNPs, all of which were associated (P-value < 0.05) with residual age at onset in the GWA data, 7 were associated (nominal P-value < 0.05) in the Fluidigm data. Missing genotypes in the Fluidigm test samples were ignored. Additionally, we also performed polygenic modification score analysis based on imputed Fluidigm test data by assigning expected genotypes based on allele frequency in the Fluidigm data. For a given missing SNP site in an individual, expected genotype in the dosage format was calculated by multiplying allele frequency of that SNP in the replication data set by 2 as described in the PLINK program manual (http://zzz.bwh.harvard.edu/plink/pro file.shtml; date last accessed July 24, 2017). The polygenic modification score was then calculated for each individual in the test samples to be used as a predictor variable of a linear regression model to explain residual age at onset of test samples. Polygenic modification score was defined as the mean of effect size of a minor allele X minor allele count based on non-missing SNPs.
Polygenic modification score analysis based on randomly chosen training and test samples from the combined data Our Fluidigm validation data set had missing data. Missing data in the test samples may reduce the accuracy of polygenic modification score when ignored or expected genotypes were assigned. To objectively evaluate the power of polygenic modification score, we 1) combined the GWA data and Fluidigm data, 2) randomly and evenly split into training samples (3,698 samples) and test samples (3,698 samples), 3) performed association analysis using genotype and residual age at onset of training samples, 4) calculated polygenic modification score of test samples based on effect size estimation from the training sample analysis and allele count of test samples, and 5) evaluated the significance of the polygenic modification score in explaining residual age at onset of test samples. This procedure was repeated 1,000 times to obtain unbiased estimations. Missing genotype data in the test samples were excluded from calculating the polygenic modification score. Scoring SNPs were based on association P-value of 0.05, 0.01, 0.001, 0.0001, and 0.00001 in the training samples. All SNPs were used as scoring SNPs as long as they passed the pre-specified significance thresholds.
Genome-wide Complex Trait Analysis (GCTA)
The overall genetic contribution to residual age at onset was calculated by the GCTA program. Briefly, GWA data were analysed by the restricted maximum likelihood (REML) method using the following parameters: -grm-adj, 0 and -grm-cutoff, 0.025. For standard GCTA analysis, all QC-passed SNPs in the GWA data were analysed. The chromosome 15:31,105,000-31,315,000 region harbors two independent genome-wide significant modification signals (11) . Therefore, this region was excluded from the GWA data to estimate the contribution of the chromosome 15 region to modification of age at onset.
Genomic Coordinates
GRCh37/hg19 was used.
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Supplementary Material is available at HMG online.
